Company / Shareholders' Equity
CANNAPHARMARX, INC. Shareholders' Equity History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$30.2M
FY2025
5-year range
-$30.2M / $17.3M
FY2021-FY2025
Trend
-52.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
CANNAPHARMARX, INC. reports negative total equity of -$30M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$30M in FY2025.
Declined from $17M to -$30M over the past 3 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 52.2% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -18.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$30.2M | -52.2% |
| FY2024 | -$19.8M | -214.2% |
| FY2022 | $17.3M | +234.2% |
| FY2021 | -$12.9M | -46.9% |
| FY2020 | -$8.8M | -281.3% |
| FY2019 | $4.9M | +1795.5% |
| FY2018 | -$286.3K | +70.3% |
| FY2017 | -$964.3K | -0.7% |
| FY2016 | -$957.7K | -39.9% |
| FY2015 | -$684.5K | -137.5% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026